Articles tagged as

Drug Manufacturers - Major

  1. Forest Laboratories: An Activist Investment Analysis

  2. Zika: Study Says This Device Could Protect You

  3. How Pharmaceutical Companies Price Their Drugs

  4. Jana Partners: An Activist Investor Analysis

  5. The Biggest Risks of Investing in Johnson & Johnson Stock (JNJ)

  6. The Biggest Risks of Investing in Celgene Stock (CELG)

  7. In Pain? Sanofi Has a Cure for That (SNY)

  8. Allergan: An Activist Investment Analysis (AGN,VRX)

  9. JNJ vs. PG: Which is the Better Bet Right Now?

  10. 2016's Most Promising Stocks (INTC, IBM)

  11. Novartis Stock: A Dividend Analysis (NVS)

  12. How Novartis Probably Has a Cure for What Ails You

  13. Are These the Top Biotech Stocks of 2016?

  14. How the New Allergan Plc Will Make Money

  15. Healthcare Stocks: Are These 2016's Best?

  16. Is Johnson & Johnson Stock Suitable for Your IRA or Roth IRA? (JNJ)

  17. The Top 5 Health Care ETFs for 2016 (XLV, VHT)

  18. The Top 5 Large-Cap Healthcare Stocks for 2016 (GILD, ANTM)

  19. PJP: PowerShares Dynamic Pharmaceuticals ETF

  20. The World's Top 10 Biotechnology Companies (JNJ, ROG.VX)

  21. CURE: Direxion Daily Healthcare Bull 3X ETF

  22. PPH: Market Vectors Pharmaceutical ETF

  23. Roche Stock: A Dividend Analysis

  24. 3 of America's Most Expensive Drugs and Who Profits From Them

  25. 4 Reasons Gilead Sciences Should be in Your Stock Portfolio (GILD)

  26. The Biggest Risks of Investing in Pfizer Stock (PFE)

  27. Johnson & Johnson Stock: A Dividend Analysis (JNJ)

  28. This Resilient Stock Should be on Your Watch List

  29. The 5 Best Dividend Stocks in the Healthcare Sector (GSK, ABBV)

  30. Top 5 Health Mutual Funds

  31. Should You Avoid Biotech Stocks Right Now? (LABD, IBB)

  32. 4 Trends Driving M&A in the Healthcare Industry in 2015

  33. Are Drug Price Controls Viable in the U.S.? (IPXL, ABBV)

  34. Healthcare M&A and Prescription Drug Prices

  35. Valeant Pharmaceuticals acquires Sprout Pharmaceuticals (VRX)

  36. Is the Ebola Epidemic Officially Over?

  37. Sarepta Therapeutics Made Investors Millionaires in 2 Years

  38. Celgene Vs. Gilead: Vetting for the Best Biopharma

  39. Make Room for Exelixis in Your Portfolio

  40. Drugmaker Extraordinaire: How Eli Lilly Grows

  41. Are Bears About to Burst the Biotech Bubble? (IBB, BIB)

  42. Pfizer CEO: The Story Behind Ian Read (PFE, AZN)

  43. 10 Developments By Gilead Sciences That Could Boost Profits (GILD)

  44. Are These 2015's 10 Best Generic Pharma Stocks?

  45. How to Profit from the Generic Drug Trend

  46. From Startup To Blue Chip: The Success Story Of Gilead Sciences Inc.

  47. Top 10 Pfizer Venture Investments (PFE)

  48. Is It Too Late To Invest In Gilead Sciences? (GILD)

  49. How Does Biogen Make its Money?

  50. Small-Cap Biotech Stocks to Watch

  51. Are These the Top 3 Value Stocks of 2015?

  52. 3 Top Pharma Stocks that Pay Regular Dividends (GSK, AZN)

  53. How to Analyze Pharma Stock Fundamentals

  54. How Bristol-Myers Squibb Makes the World Healthier

  55. How is a Spinoff Worth $100 Billion? See AbbVie

  56. Why These Could Be 2015's 10 Best Biotech Stocks

  57. Why These Could Be 2015's 10-Best Pharma Stocks (ABBV, ALXN)

  58. Why These ETFs are the Best Way to Trade Pfizer

  59. Could Amgen's Next Drug Be Worth $100 Billion?

  60. Has The Time Come To Sell Vertex Pharmaceuticals?

  61. Why Celgene Won't Pay A Dividend Anytime Soon

  62. Could This Drug Make Isis Pharmaceuticals Soar?

  63. What Biotech Stock To Buy When The Market Tumbles?

  64. Did Orexigen Make A Big Mistake?

  65. Are These Biogen Idec's Next Blockbusters?

  66. Why Does Wall Street Hate MannKind?

  67. Is Exelixis Under-the-Radar Growth?

  68. Is Arena Pharmaceuticals In Trouble? (ARNA)

  69. What’s The Drug That Will Finally Fight Obesity?

  70. Should You Invest In Oraganovo Holdings?

  71. What Is Amgen’s New Target?

  72. Will MannKind Finally Reach A Solid Ground?

  73. Should We Be Concerned For Sarepta’s Share Prices? (SRPT)

  74. What Are The Real Economic Costs Of Obesity?

  75. Gilead Sciences: The New Market-Share Leader

  76. Sun Pharma And Ranbaxy: An Ideal Pharma Marriage?

  77. Dilip Shanghvi's Net Worth: How Did He Get So Rich?

  78. How Amgen Makes Billions On Just A Few Drugs

  79. How Merck Found Its Way Into Millions Of Medicine Cabinets

  80. How Gilead Sciences Became A Big Name In Biotech

  81. Want To Make Money In Marijuana? Read This First

  82. What Are The Best Bets In Biotech?

  83. How Some Brands Come Back from Near Death

  84. It's No Accident That Drugs Are Expensive

  85. Will Immunotherapy Disrupt The Oncology Market?

  86. 8 Stages Of New Drug Development

  87. Big Pharma Faces 'Pay For Delay' Lawsuits

Trading Center